Description

Retatrutide 10 mg is a higher-strength formulation of the investigational peptide currently in Phase 3 clinical trials for obesity and Type 2 diabetes. Retatrutide acts as a triple receptor agonist (GLP-1, GIP, and glucagon), making it one of the most promising next-generation treatments for weight loss, appetite control, and metabolic health.

While clinical trials officially study doses up to 12 mg weekly, the 10 mg strength is widely offered by research and compounding suppliers. It is typically positioned as a maintenance or escalation dose for studies following lower starting doses (2 mg → 4 mg → 8 mg).